Results 81 to 90 of about 3,595 (167)

Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study

Infectious Diseases and Therapy
Introduction Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic courses.
Nicholas Rebold, Sara Alosaimy, Jeffrey C. Pearson, Brandon Dionne, Ahmad Taqi, Abdalhamid Lagnf, Kristen Lucas, Mark Biagi, Nicholas Lombardo, Joshua Eudy, Daniel T. Anderson, Monica V. Mahoney, Wesley D. Kufel, Joseph A. D’Antonio, Bruce M. Jones, Jeremy J. Frens, Tyler Baumeister, Matthew Geriak, George Sakoulas, Dimitrios Farmakiotis, Dino Delaportas, Jeremy Larew, Michael P. Veve, Michael J. Rybak   +23 more
doaj   +1 more source

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin

Therapeutics and Clinical Risk Management, 2016
Janelle J Juul, Caitlin F Mullins, William J Peppard, Angela M Huang Department of Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, USA Abstract: Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug ...
Juul JJ, Mullins CF, Peppard WJ, Huang AM   +3 more
doaj  

A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis

Infection
Dalbavancin is an antibiotic characterized by an extended half-life and efficacy against methicillin-resistant Staphylococci. Currently, there are only narrative reviews summarizing the evidence about the use of dalbavancin for infective endocarditis (IE)
Gabriele Maria Leanza, E. Rando, Federico Frondizi, Eleonora Taddei, F. Giovannenze, J. Horcajada, Giancarlo Scoppettuolo, Carlo Torti   +7 more
semanticscholar   +1 more source

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

Drug Design, Development and Therapy, 2021
Milo Gatti,1,2 Massimo Andreoni,3,4 Federico Pea,1,2 Pierluigi Viale1,5 1Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 2SSD Clinical Pharmacology, IRCCS Azienda Ospedaliero-Universitaria di ...
Gatti M, Andreoni M, Pea F, Viale P
doaj  

Questioning the Design of Non‐Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials

Clinical Pharmacology &Therapeutics, Volume 117, Issue 1, Page 25-27, January 2025.
Florian Lemaitre, Sébastien Lalanne, Marie‐Clémence Verdier   +2 more
wiley   +1 more source

Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user

International Journal of Infectious Diseases, 2018
This report describes the treatment of a 35-year-old male who presented to the emergency department with an empyema, and who had a long hospital course complicated by a catheter-related bloodstream infection and a history of intravenous drug use.
Bruce M. Jones, Chelsea Keedy, Melissa Wynn   +2 more
doaj   +1 more source

Genome-wide CRISPRi screens for high-throughput fitness quantification and identification of determinants for dalbavancin susceptibility in Staphylococcus aureus

mSystems
Antibiotic resistance and tolerance remain a major problem for the treatment of staphylococcal infections. Identifying genes that influence antibiotic susceptibility could open the door to novel antimicrobial strategies, including targets for new ...
Xue Liu, Vincent de Bakker, Maria Victoria Heggenhougen, M. T. Mårli, Anette Heidal Frøynes, Z. Salehian, D. Porcellato, Danae Morales Angeles, J. Veening, M. Kjos   +9 more
semanticscholar   +1 more source

Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-2: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Acetate Buffer with and Without Divalent Metal Ions

Pharmaceutics
Objectives: The effect of 2-hydroxpropyl-β-cyclodextrin (2HPβCD) with or without divalent metal ions (Ca2+, Mg2+, and Zn2+) on the stability of dalbavancin in acetate buffer was investigated.
Sardar M. Jakaria, David E. Budil, James Murtagh, Graham Revilla   +3 more
doaj   +1 more source

Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

Journal of Global Antimicrobial Resistance
: Objectives: We report the use of IV dalbavancin in Canadian patients using data captured by the national CLEAR registry. Methods: The CLEAR registry uses the web-based data management program, REDCap™ (online survey https://rcsurvey.radyfhs.umanitoba ...
George Zhanel, Michael Silverman, Janhavi Malhotra, Melanie Baxter, Reza Rahimi, Neal Irfan, Gabriel Girouard, Rita Dhami, Melissa Kucey, Vida Stankus, Kristin Schmidt, Sébastien Poulin, William Connors, Carlo Tascini, Andrew Walkty, James Karlowsky   +15 more
doaj   +1 more source

P-744. Admission Avoidance: A Protocol for Using Dalbavancin in the Emergency Department for Acute Bacterial Skin and Skin Structure Infections

Open Forum Infectious Diseases
Background Dalbavancin is a glycopeptide with a 14.4 day terminal half-life that has been used previously in our institution to facilitate early discharge for acute bacterial skin and skin structure infections (ABSSSI). We have expanded this program with
Katherine Weller, Christopher M. Bland, Bruce M. Jones   +2 more
semanticscholar   +1 more source